https://orcid.org/0000-0001-7050-0797
References
- Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020 Mar;69(3):564–568.
- Alonso C, Fernandez-Ramos D, Varela-Rey M, et al. metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology. 2017 May;152(6):1449–1461 e7.
- Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 Oct;71(4):823–833.
- Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2018 Feb;68(2):230–237.
- Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol. 2020 Apr;29. DOI:10.1016/j.jhep.2020.04.025
- Puengel T, De Vos S, Hundertmark J, et al. The medium-chain fatty acid receptor GPR84 mediates myeloid cell infiltration promoting steatohepatitis and fibrosis. J Clin Med. 2020 Apr 16;9(4). DOI:10.3390/jcm9041140.
- Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020 Mar;6. DOI:10.1016/j.jhep.2020.02.027
- Roth JD, Veidal SS, Fensholdt LKD, et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep. 2019 Jun 21;9(1):9046.
- Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 Antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11(6):e0158156. .
- Ijssennagger N, Janssen AWF, Milona A, et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. J Hepatol. 2016;64(5):1158–1166. .
- Ouchi R, Togo S, Kimura M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab. 2019 Aug 6;30(2):374–384 e6.
- Hassan S, Sebastian S, Maharjan S, et al. Liver-on-a-chip models of fatty liver disease. Hepatology. 2020 Feb;71(2):733–740.
- Gori M, Simonelli MC, Giannitelli SM, et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS One. 2016;11(7):e0159729. .
- Kostrzewski T, Cornforth T, Snow SA, et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol. 2017 Jan 14;23(2):204–215.
- Teufel A, Itzel T, Erhart W, et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology. 2016 Sep;151(3):513–525 e0.
- Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 May;158(7):1999–2014 e1.
- Farrell GC, Mridha AR, Yeh MM, et al. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver Int. 2014 Aug;34(7):1084–1093.